Dr. Shah and his team have pioneered major developments in translational cell therapy field, successfully developing gene edited and engineered cellular therapies for cancer. His early work on engineered stem cell for brain tumor therapy work drew widespread international attention, with features on BBC and CNN. In recent years, Dr. Shah’s laboratory has taken a bold and unconventional approach by reverse-engineering cancer cells and repurpose them as therapeutic agents to fight cancer. This work has been highlighted in Scientific American, New York Times, Boston Herald and Sky News, reflecting both its novelty and clinical potential. Dr. Shah has authored two books exploring groundbreaking strategies for treating cancer using engineered cell types. A sought-after speaker, he has delivered over 300 presentations worldwide and regularly gives keynote lectures focused on innovation and the clinical translation of biological therapies.  

Dr. Shah’s contributions have been widely recognized by many cancer alliances and associations earning him numerous honors including young investigator, mentorship, distinguished research, innovation, and impact awards. Beyond research, Dr. Shah plays an active role in shaping the field through service on multiple councils, advisory groups, and editorial boards in cell therapy and oncology. Dr. Shah has trained a diverse cohort of graduate students and residents from across the US and more than 50 countries. Dr. Shah currently holds numerous patents, and has founded two biotech companies dedicated to advancing therapeutic cell technologies into clinical applications for cancer patients. A prolific innovator, published researcher and author, Dr. Shah is committed  to harness “out of the box” for cancer.  

More details about Dr. Shah’s work can be found at: 

Cell-Based Immunotherapy - Center for Stem Cell and Translational Immunotherapy (CSTI) (harvard.edu)